Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Liquidia Corp’s Chief Commercial Officer, Scott Moomaw, reported stock activity involving performance stock units (PSUs) and common shares. On January 9, 2026, PSUs converted into 3,108 and 17,433 shares of common stock at an exercise price of $0, reflecting vesting of prior PSU awards that convert into common stock on a one-for-one basis. Following these conversions, he held 175,047 shares directly. On January 12, 2026, he sold 20,533 common shares at $37.43 per share, leaving 154,514 shares held directly. According to the disclosure, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023 and the shares were sold to cover taxes tied to the settlement of restricted stock units granted in 2023, 2024, and 2025.
Liquidia Corp executive Michael Kaseta, the CFO and COO, reported equity award vesting and a related stock sale. On January 9, 2026, performance stock units converted into 5,828 and 28,200 shares of Liquidia common stock on a one-for-one basis. These conversions stem from PSU grants made in 2024 and 2025 that vest over several years.
On January 12, 2026, Kaseta sold 36,932 shares of common stock at $37.43 per share, with ownership listed as direct and 350,919 shares beneficially owned afterward. The sale was executed under a Rule 10b5-1 trading plan adopted on December 15, 2023, and the shares were sold to cover taxes associated with the settlement of restricted and performance stock units from multiple prior grant dates.
Liquidia Corp Chief Business Officer Jason Adair reported equity award vesting and a related share sale. On January 9, 2026, performance stock units and restricted stock units converted into several blocks of common stock, including 3,906, 2,474 and 15,474 shares, as part of previously granted RSU and PSU awards that vest over multi‑year schedules.
On January 12, 2026, Adair sold 13,548 shares of common stock at $37.43 per share in a transaction carried out under a pre‑arranged Rule 10b5‑1 plan adopted on December 15, 2023. According to the disclosure, these shares were sold to cover taxes tied to the settlement of RSUs and PSUs granted in 2023, 2024 and 2025. After these transactions, Adair directly held 184,174 shares of Liquidia common stock, along with additional unvested RSUs and PSUs.
Liquidia Corp (LQDA) General Counsel Russell Schundler reported equity award vesting and a related share sale. On January 9, 2026, performance stock units converted into 3,759 and 25,636 shares of common stock at an exercise price of $0 per share, increasing his directly held common stock to 606,683 shares. On January 12, 2026, he sold 27,289 shares of common stock at $37.43 per share under a Rule 10b5-1 trading plan adopted on December 15, 2023, primarily to cover taxes tied to RSU and PSU settlements, leaving 579,394 shares held directly. The filing also notes an additional 14,500 shares held indirectly by his spouse, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Liquidia Corp’s Chief Executive Officer and director Roger Jeffs reported equity award vesting and a related stock sale. On January 9, 2026, performance stock units converted into 13,833 and 57,332 shares of common stock, reflecting previously granted PSUs that vest over multi-year schedules. The filing notes that PSUs convert into common stock on a one-for-one basis.
On January 12, 2026, Jeffs sold 66,610 shares of Liquidia common stock at $37.43 per share in a transaction effected under a pre-established Rule 10b5-1 plan. According to the footnotes, these shares were sold to cover taxes tied to the settlement of RSUs and PSUs granted in 2023, 2024 and 2025. After these transactions, he directly held 1,037,528 common shares, with additional indirect holdings through a living trust and Serendipity BioPharma LLC.
Liquidia Corp’s Chief Accounting Officer, Dana Boyle, reported routine equity transactions. On January 9, 2026, 12,716 performance stock units converted into the same number of shares of common stock at an exercise price of $0, reflecting scheduled PSU vesting. On January 12, 2026, Boyle sold 11,047 shares of common stock at $37.43 per share, leaving 156,700 common shares beneficially owned afterward. The sale was made under a pre‑arranged Rule 10b5‑1 plan and was used to cover taxes tied to the settlement of previously granted RSUs and PSUs. Following these transactions, Boyle continued to hold 38,145 performance stock units in addition to other unvested equity awards.
Liquidia Corp Chief Medical Officer Dr. Rajeev Saggar reported equity award activity and a related share sale. On January 9, 2026, performance stock units (PSUs) converting on a one-for-one basis were settled into 3,531 and 17,945 shares of common stock at an exercise price of $0, increasing his directly held common stock to 198,025 shares. On January 12, 2026, he sold 21,142 shares of common stock at $37.43 per share, leaving 176,883 shares held directly afterward. The footnotes state this sale was effected under a Rule 10b5-1 trading plan adopted on December 15, 2023 and that the shares were sold to cover taxes associated with the settlement of equity awards granted in 2023, 2024 and 2025.
Liquidia Corporation’s Chief Development Officer, Sanjeev Khindri, filed a Form 3 disclosing his initial beneficial ownership in the company. He is reported as directly beneficially owning 36,992 shares of common stock, tied to restricted stock units (RSUs) that convert into common stock on a one-for-one basis. These 36,992 RSUs were granted on February 10, 2025, with 25% scheduled to vest approximately one year after the grant date and the remaining units vesting ratably on a quarterly basis over the following three years. As of the Form 3 filing date, none of these RSUs have vested.
Liquidia Corporation filed a current report stating that it has issued a press release with its preliminary financial results for the quarter ended December 31, 2025 and a corporate update. The company furnished this press release as Exhibit 99.1 to the filing, indicating that the details are provided for informational purposes and are not deemed filed under certain liability provisions of the securities laws.
Liquidia Corp (LQDA) reported an insider equity transaction by its Chief Business Officer on a Form 4. On 11/18/2025, the officer exercised stock options to acquire a total of 35,656 shares of common stock at an exercise price of $5.89 per share and then sold 35,656 shares of common stock in a market transaction. The sale price was a volume-weighted average of $30.0289 per share for trades between $30.00 and $30.15, executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 29, 2025.
Following these transactions, the officer beneficially owned 174,998 shares of Liquidia common stock directly. This amount includes unvested restricted stock units granted in 2023, 2024 and 2025, as well as shares acquired under the company’s 2020 Employee Stock Purchase Plan.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
